Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria-tetanus-pertussis + Sabin inactivated poliovirus combined vaccine
- Development stage
- Unknown
- Lead developer
- Sinopharm Zhongsheng Biotechnology Research Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This investigational combination vaccine, developed by the **Wuhan Institute of Biological Products** and **Sinopharm Zhongyuan Biological Technology Research Institute** (subsidiaries of **Sinopharm**), is designed to protect against four major childhood diseases: diphtheria, tetanus, pertussis, and poliomyelitis. It combines an adsorbed acellular pertussis, diphtheria, and tetanus (DTaP) component with an inactivated poliovirus vaccine (IPV) derived from Sabin strains (sIPV). The use of Sabin strains for the IPV component is a significant feature, as it enhances manufacturing biosafety compared to traditional Salk-strain IPV. The vaccine is currently undergoing Phase 1 clinical evaluation in China to assess its safety and immunogenicity in infants and children.
- Other names
- DTaP-sIPVadsorbed acellular diphtheria-tetanus-pertussis and Sabin inactivated poliovirus combined vaccine
02
Targets
Diphtheria toxinPV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on adsorbed acellular diphtheria-tetanus-pertussis + Sabin inactivated poliovirus combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria-tetanus-pertussis + Sabin inactivated poliovirus combined vaccine.